Status:
COMPLETED
Kinetics of B Cell Response in Infants Menjugate Vaccination
Lead Sponsor:
Novartis
Collaborating Sponsors:
Novartis Vaccines
Conditions:
Prevention of Meningococcal Infection
Eligibility:
All Genders
8-11 years
Phase:
PHASE4
Brief Summary
Kinetics of B cell response in infants Menjugate vaccination
Eligibility Criteria
Inclusion
- healthy infants
Exclusion
- previously ascertained or suspected disease caused by N. meningitidis
- previous household contact with an individual with a positive culture of N. meningitidis serogroup C
Key Trial Info
Start Date :
May 1 2005
Trial Type :
INTERVENTIONAL
End Date :
November 1 2005
Estimated Enrollment :
75 Patients enrolled
Trial Details
Trial ID
NCT00310700
Start Date
May 1 2005
End Date
November 1 2005
Last Update
September 19 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital
Oxford, Oxon, United Kingdom, OX3 7LJ